Finrozole

CAS No. 160146-17-8

Finrozole( —— )

Catalog No. M34254 CAS No. 160146-17-8

Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 198 Get Quote
5MG 304 Get Quote
10MG 456 Get Quote
25MG 723 Get Quote
50MG 994 Get Quote
100MG 1332 Get Quote
500MG 2664 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Finrozole
  • Note
    Research use only, not for human use.
  • Brief Description
    Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.
  • Description
    Finrozole (MPV-2213ad) is a nonsteroidal, orally active and competitive aromatase enzyme inhibitor. Finrozole can be used for urinary symptoms research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Aromatase
  • Recptor
    Aromatase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    160146-17-8
  • Formula Weight
    322.34
  • Molecular Formula
    C18H15FN4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H]([C@H](CC1=CC=C(F)C=C1)O)(C2=CC=C(C#N)C=C2)N3C=NC=N3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. O Ahokoski, et al. Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4.?
molnova catalog
related products
  • Finrozole

    Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.

  • 3,4-Dimethoxyhydroci...

    It is an organic compunds with molecular fomula C11H14O4.

  • Letrozole

    Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme.